# US 2016/0250146 A1 · Hydrophobic Drug-Delivery Material, Method for Manufacturing Thereof and Methods for Delivery of a Drug-Delivery Composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250146 A1
- Document ID: US20160250146A1
- Status: Published application
- Kind: A1
- Application number: 15/083,879
- Filed: 2016-03-29
- Published: 2016-09-01
- Earliest claimed: 2011-11-30
- Inventors: Andreas Voigt; Scott Hampton; Andreas Reiff; Sonja Lehmann; Joerg Kriwanek
- Web page: https://patentgrep.com/patent/US20160250146A1

## CPC

- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 23/00: Anaesthetics
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/10: Antimycotics
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.

## Claims

### Claim 1

A method for manufacturing a drug-delivery composition, comprising:
providing at least a pharmaceutically active composition;
providing a hydrophobic matrix; and
mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.

### Claim 2 (depends on 1)

The method according to claim 1, wherein providing the hydrophobic matrix comprises mixing of at least a hydrophobic solid component and a hydrophobic liquid component.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising:
providing the pharmaceutically active composition as dry pharmaceutically active composition powder; and
homogeneous mixing the hydrophobic matrix with the dry pharmaceutically active composition powder to form the paste-like or semi-solid drug delivery composition.

### Claim 4 (depends on 1)

The method according to claim 1, further comprising:
providing the pharmaceutically active composition in a dissolved state; and
homogeneous mixing the hydrophobic matrix with the dissolved pharmaceutically active composition to form the paste-like or semi-solid drug-delivery composition.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the pharmaceutically active composition comprises at least a pharmaceutically active compound and at least one excipient selected from the group consisting of monosaccharides, disaccharides, oligosaccharides, polysaccharides like hyaluronic acid, pectin, gum arabic and other gums, albumin, chitosan, collagen, collagen-n-hydroxysuccinimide, fibrin, fibrinogen, gelatin, globulin, polyaminoacids, polyurethane comprising amino acids, prolamin, protein-based polymers, copolymers and derivatives thereof, and mixtures thereof.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the pharmaceutically active composition comprises at least a pharmaceutically active compound without any excipients.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the forming of the paste-like or semi-solid drug-delivery composition includes repeated cycles of pressing and folding, in an algorithmic manner, of the mixture of the hydrophobic matrix and the pharmaceutically active composition.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the dissolved pharmaceutically active composition is added step-wise during mixing comprising repeated pressing and folding of the mixture of the hydrophobic matrix and the pharmaceutically active composition.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the pressing applies a pressure of not more than 106 N·m−2.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the pharmaceutically active composition is dissolved in an aqueous solution before being mixed with the hydrophobic matrix.

### Claim 11 (depends on 1)

The method according to claim 1, further comprising one of:
simultaneous mixing of at least a hydrophobic solid component, a hydrophobic liquid component, and the pharmaceutically active composition dissolved in an aqueous solution to form the paste-like or semi-solid drug-delivery composition; and
mixing of at least a hydrophobic solid component and a hydrophobic liquid component to form the hydrophobic matrix, and adding the pharmaceutically active composition dissolved in an aqueous solution to the hydrophobic matrix to form the paste-like or semi-solid drug-delivery composition.

### Claim 12 (depends on 3)

The method according to claim 3, wherein the pharmaceutical active composition powder comprises particles in a size range from about 100 nm to about 50 μm.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the hydrophobic matrix comprises a solid component and a liquid hydrophobic component,
wherein the solid component is selected from waxes, fruit wax, carnauba wax, bees wax, waxy alcohols, plant waxes, soybean waxes, synthetic waxes, triglycerides, lipids, long-chain fatty acids and their salts like magnesium stearate, magnesium palmitate, esters of long-chain fatty acids, long-chain alcohols like cetyl palmitate, waxy alcohols, long-chain alcohols like cetylalcohol, oxethylated plant oils, oxethylated fatty alcohols, and
wherein the liquid hydrophobic component is selected from plant oils, castor oil, jojoba oil, soybean oil, silicon oils, paraffin oils, and mineral oils, cremophor, oxethylated plant oils, oxethylated fatty alcohols.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the pharmaceutically active composition comprises a pharmaceutically active compound selected from the group consisting of immunoglobulins, fragments or fractions of immunoglobulins, synthetic substance mimicking immunoglobulins or fragments or fractions thereof, proteins peptides having a molecular mass equal to or higher than 3 kDa, ribonucleic acids (RNA), desoxyribonucleic acids (DNA) including aptamers and spiegelmers, plasmids, peptide nucleic acids (PNA), steroids, and corticosteroids.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the pharmaceutically active composition comprises a pharmaceutically active compound selected from the group consisting of immunoglobulins, fragments or fractions of immunoglobulins, synthetic substance mimicking immunoglobulins or synthetic, semisynthetic or biosynthetic fragments or fractions thereof, chimeric, humanized or human monoclonal antibodies, Fab fragments, fusion proteins or receptor antagonists (e.g., anti TNF alpha, Interleukin-1, Interleukin-6 etc.), antiangiogenic compounds (e.g., anti-VEGF, anti-PDGF etc.), intracellular signaling inhibitors (e.g JAK1,3 and SYK inhibitors), peptides having a molecular mass equal to or higher than 3 kDa, ribonucleic acids (RNA), desoxyribonucleic acids (DNA), plasmids, peptide nucleic acids (PNA), steroids, corticosteroids, an adrenocorticostatic, an antibiotic, an antidepressant, an antimycotic, a [beta]-adrenolytic, an androgen or antiandrogen, an antianemic, an anabolic, an anaesthetic, an analeptic, an antiallergic, an antiarrhythmic, an antiarterosclerotic, an antibiotic, an antifibrinolytic, an anticonvulsive, an antiinflammatory drug, an anticholinergic, an antihistaminic, an antihypertensive, an antihypotensive, an anticoagulant, an antiseptic, an antihemorrhagic, an antimyasthenic, an antiphlogistic, an antipyretic, a beta-receptor antagonist, a calcium channel antagonist, a cell, a cell differentiation factor, a chemokine, a chemotherapeutic, a coenzyme, a cytotoxic agent, a prodrug of a cytotoxic agent, a cytostatic, an enzyme and its synthetic or biosynthetic analogue, a glucocorticoid, a growth factor, a haemostatic, a hormone and its synthetic or biosynthetic analogue, an immunosuppressant, an immunostimulant, a mitogen, a physiological or pharmacological inhibitor of mitogens, a mineralcorticoid, a muscle relaxant, a narcotic, a neurotransmitter, a precursor of a neurotransmitter, an oligonucleotide, a peptide, a (para)-sympathicomimetic, a (para)-sympatholytic, a protein, a sedating agent, a spasmolytic, a vasoconstrictor, a vasodilatator, a vector, a virus, a virus-like particle, a virustatic, a wound-healing substance, and combinations thereof.

### Claim 16 (depends on 1)

The method according to claim 1, further comprising:
forming the drug-delivery composition into an applicable form.

### Claim 17

A drug-delivery composition, comprising:
a paste-like or semi-solid mixture comprising at least a hydrophobic matrix and a pharmaceutically active compound.

### Claim 18 (depends on 17)

The drug-delivery composition according to claim 17, wherein the pharmaceutically active compound is dispersed in the hydrophobic matrix in particulate form.

### Claim 19 (depends on 17)

The drug-delivery composition according to claim 17, wherein the pharmaceutically active compound is dispersed in the hydrophobic matrix in a dissolved state.

### Claim 20 (depends on 19)

The drug-delivery composition according to claim 19, wherein the pharmaceutically active compound is dissolved in a solution comprising water and electrolytes.

### Claim 21 (depends on 19)

The drug-delivery composition according to claim 19, wherein the pharmaceutically active compound is dissolved in a solution comprising water, electrolytes and at least one of monosaccharides, disaccharides, oligosaccharides, polysaccharides like hyaluronic acid, pectin, gum arabic and other gums, albumin, chitosan, collagen, collagen-n-hydroxysuccinimide, fibrin, fibrinogen, gelatin, globulin, polyaminoacids, polyurethane comprising amino acids, prolamin, protein-based polymers, copolymers and derivatives thereof, and mixtures thereof.

### Claim 22 (depends on 17)

The drug-delivery composition according to claim 17, wherein the paste-like or semi-solid mixture has a modulus of elasticity at least of 10−4N·mm−2.

### Claim 23 (depends on 17)

The drug-delivery composition according to claim 17, wherein the paste-like or semi-solid mixture has a viscosity of at least 100 mPa·s.

### Claim 24 (depends on 17)

The drug-delivery composition according to claim 17, wherein the pharmaceutically active compound is selected from the group consisting of immunoglobulins, fragments or fractions of immunoglobulins, synthetic substance mimicking immunoglobulins or fragments or fractions thereof, proteins, peptides having a molecular mass equal to or higher than 3 kDa, ribonucleic acids (RNA), desoxyribonucleic acids (DNA), plasmids, peptide nucleic acids (PNA), aptamers, spiegelmers, steroids, and corticosteroids.

### Claim 25 (depends on 17)

The drug-delivery composition according to claim 17, wherein the pharmaceutically active compound is selected from the group consisting of: immunoglobulins, fragments or fractions of immunoglobulins, synthetic substance mimicking immunoglobulins or synthetic, semisynthetic or biosynthetic fragments or fractions thereof, chimeric, humanized or human monoclonal antibodies, Fab fragments, fusion proteins or receptor antagonists (e.g., anti TNF alpha, Interleukin-1, Interleukin-6 etc.), antiangiogenic compounds (e.g., anti-VEGF, anti-PDGF etc.), intracellular signaling inhibitors (e.g JAK1,3 and SYK inhibitors), peptides having a molecular mass equal to or higher than 3 kDa, ribonucleic acids (RNA), desoxyribonucleic acids (DNA), plasmids, peptide nucleic acids (PNA), steroids, corticosteroids, an adrenocorticostatic, an antibiotic, an antidepressant, an antimycotic, a [beta]-adrenolytic, an androgen or antiandrogen, an antianemic, an anabolic, an anaesthetic, an analeptic, an antiallergic, an antiarrhythmic, an antiarterosclerotic, an antibiotic, an antifibrinolytic, an anticonvulsive, an antiinflammatory drug, an anticholinergic, an antihistaminic, an antihypertensive, an antihypotensive, an anticoagulant, an antiseptic, an antihemorrhagic, an antimyasthenic, an antiphlogistic, an antipyretic, a beta-receptor antagonist, a calcium channel antagonist, a cell, a cell differentiation factor, a chemokine, a chemotherapeutic, a coenzyme, a cytotoxic agent, a prodrug of a cytotoxic agent, a cytostatic, an enzyme and its synthetic or biosynthetic analogue, a glucocorticoid, a growth factor, a haemostatic, a hormone and its synthetic or biosynthetic analogue, an immunosuppressant, an immunostimulant, a mitogen, a physiological or pharmacological inhibitor of mitogens, a mineralcorticoid, a muscle relaxant, a narcotic, a neurotransmitter, a precursor of a neurotransmitter, an oligonucleotide, a peptide, a (para)-sympathicomimetic, a (para)-sympatholytic, a protein, a sedating agent, a spasmolytic, a vasoconstrictor, a vasodilatator, a vector, a virus, a virus-like particle, a virustatic, a wound-healing substance, and combinations thereof.

### Claim 26 (depends on 17)

The drug-delivery composition according to claim 17, wherein the hydrophobic matrix comprises at least a hydrophobic solid component and a hydrophobic liquid component, wherein the mass ratio of the hydrophobic solid component to the hydrophobic liquid component is below 2.8:1.

### Claim 27 (depends on 17)

The drug-delivery composition according to claim 17, wherein the mass of the pharmaceutically active compound is up to 25% (w/w) of the total mass of the paste-like or semi-solid mixture.

### Claim 28 (depends on 17)

The drug-delivery composition according to claim 17, wherein the mass of the pharmaceutically active compound is at least 0.01% (w/w) of the total mass of the paste-like or semi-solid mixture.

### Claim 29

A method for delivery a drug-delivery composition, comprising:
providing a drug-delivery composition comprising a paste-like or semi-solid mixture comprising at least a hydrophobic matrix and a pharmaceutically active compound; and
applying the drug-delivery composition into a human or animal body.

### Claim 30 (depends on 29)

The method of claim 29, wherein applying the mixture into the human or animal body comprises at least one of:
implanting or injecting the mixture into a human or animal body;
intraocular injecting the mixture into a human, or animal body;
subcutaneous injecting the mixture into a human, or animal body;
intramuscular injecting the mixture into a human, or animal body;
intraperitoneal injecting the mixture into a human, or animal body;
intravenous injecting the mixture into a human, or animal body;
inhalative administering the mixture into a human, or animal body; and
intranasal administering the mixture into a human, or animal body.
